Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey

Cancer

Volumn 107, Issue 10, 2006, Pages 2504-2511

  Demierre, Marie France ^a,c   Gan, Stephanie ^a   Jones, Judy ^b   Miller, Donald R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cutaneous Lymphoma Foundation   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cutaneous T cell lymphoma; Health distress; Physical and emotional well being; Role functioning

Indexed keywords

BEXAROTENE; CARMUSTINE; CHLORMETHINE; DENILEUKIN DIFTITOX; METHOTREXATE; STEROID;

ADULT; AGED; ARTICLE; COST OF ILLNESS; DISTRESS SYNDROME; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SKIN LYMPHOMA; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; T CELL LYMPHOMA; WELLBEING;

ADAPTATION, PHYSIOLOGICAL; ADULT; AGED; FEMALE; FOUNDATIONS; HEALTH STATUS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; SKIN NEOPLASMS;

EID: 33750976203     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22252     Document Type: Article

References (13)

1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978-1988.
2. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003;17:1485-1507.
3. Demierre MF, Tien A, Miller DR. Health-related quality of life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141:325-330.
4. Demierre MF, Ferzli P, Miller DR. HRQOL measures in cutaneous T-cell lymphoma patients undergoing therapy with Bexarotene and extracorporeal photopheresis. Arch Dermatol. In press.
5. Zackheim HS, Koh HK, Weinstock MA. Assessing clinical outcomes in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1021-1029.
6. Evers AWM, Lu Y, Duller P, van der Valk PGM, Kraaimaat FW, van de Kerkhof PCM. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275-1281.
7. Fortune DG, Richards HL, Kirby B, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol. 2003;139:752-756.
8. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458-465.
9. Duvic M, Kuzel TM, Olsen EA, et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma. 2002;2:222-228.
10. Chren M-M. Measurement of vital signs for skin diseases. J Invest Dermatol. 2005;125:viii-ix.
11. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst. 2003;95:263-281.
12. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA. 1988;260:42-46.
13. U.S. Food and Drug Administration. Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/cder/guidance/5460dft.pdf (accessed May 10, 2006).